Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9851 |
High Similarity |
NPD2800 |
Approved |
0.8978 |
High Similarity |
NPD6651 |
Approved |
0.869 |
High Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8562 |
High Similarity |
NPD2533 |
Approved |
0.8562 |
High Similarity |
NPD2532 |
Approved |
0.8562 |
High Similarity |
NPD2534 |
Approved |
0.8435 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8235 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8207 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8207 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8182 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8169 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8151 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8095 |
Intermediate Similarity |
NPD1243 |
Approved |
0.8069 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8056 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8039 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8038 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.8027 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8014 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7987 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7962 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7961 |
Intermediate Similarity |
NPD920 |
Approved |
0.7959 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7935 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7922 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7919 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7898 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7895 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7885 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7885 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7875 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7875 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7848 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7821 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.78 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7778 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.777 |
Intermediate Similarity |
NPD6099 |
Approved |
0.777 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7763 |
Intermediate Similarity |
NPD6799 |
Approved |
0.775 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7748 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7736 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7712 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7703 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7697 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7665 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7636 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7616 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7584 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7576 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7561 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7561 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7561 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7546 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7534 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7533 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.753 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7515 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD2654 |
Approved |
0.7467 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7455 |
Intermediate Similarity |
NPD2403 |
Approved |
0.7451 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7451 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.744 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7419 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7405 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7394 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7381 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7378 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7368 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7362 |
Intermediate Similarity |
NPD919 |
Approved |
0.7346 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7343 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7321 |
Intermediate Similarity |
NPD7054 |
Approved |
0.731 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7305 |
Intermediate Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7278 |
Intermediate Similarity |
NPD1729 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7267 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7235 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD3972 |
Approved |
0.7222 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7219 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.72 |
Intermediate Similarity |
NPD943 |
Approved |
0.7193 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7191 |
Intermediate Similarity |
NPD4362 |
Clinical (unspecified phase) |
0.7191 |
Intermediate Similarity |
NPD4361 |
Phase 2 |
0.7181 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7181 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7178 |
Intermediate Similarity |
NPD2296 |
Approved |
0.7172 |
Intermediate Similarity |
NPD4749 |
Approved |
0.717 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7162 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.7151 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7135 |
Intermediate Similarity |
NPD4360 |
Phase 2 |
0.7135 |
Intermediate Similarity |
NPD4363 |
Phase 3 |
0.7123 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7093 |
Intermediate Similarity |
NPD6104 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7073 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7052 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7044 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7044 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7039 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7034 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7024 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7013 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7013 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7012 |
Intermediate Similarity |
NPD5760 |
Phase 2 |
0.7012 |
Intermediate Similarity |
NPD5761 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.6994 |
Remote Similarity |
NPD3658 |
Clinical (unspecified phase) |
0.6989 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6986 |
Remote Similarity |
NPD1608 |
Approved |
0.6975 |
Remote Similarity |
NPD7458 |
Discontinued |
0.697 |
Remote Similarity |
NPD4288 |
Approved |
0.6959 |
Remote Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD3764 |
Approved |
0.6954 |
Remote Similarity |
NPD411 |
Approved |
0.6954 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6936 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.6903 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6899 |
Remote Similarity |
NPD7003 |
Approved |
0.689 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6879 |
Remote Similarity |
NPD1241 |
Discontinued |
0.6875 |
Remote Similarity |
NPD1548 |
Phase 1 |
0.6875 |
Remote Similarity |
NPD9545 |
Approved |
0.6867 |
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD5408 |
Approved |
0.6859 |
Remote Similarity |
NPD5405 |
Approved |
0.6859 |
Remote Similarity |
NPD5406 |
Approved |
0.6859 |
Remote Similarity |
NPD5404 |
Approved |
0.6853 |
Remote Similarity |
NPD9493 |
Approved |
0.6848 |
Remote Similarity |
NPD6280 |
Approved |
0.6848 |
Remote Similarity |
NPD6279 |
Approved |
0.6846 |
Remote Similarity |
NPD3266 |
Approved |
0.6846 |
Remote Similarity |
NPD1164 |
Approved |
0.6846 |
Remote Similarity |
NPD3267 |
Approved |
0.6821 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6803 |
Remote Similarity |
NPD1201 |
Approved |
0.68 |
Remote Similarity |
NPD1019 |
Discontinued |
0.6781 |
Remote Similarity |
NPD17 |
Approved |
0.6779 |
Remote Similarity |
NPD3225 |
Approved |
0.6779 |
Remote Similarity |
NPD1876 |
Approved |
0.6779 |
Remote Similarity |
NPD8651 |
Approved |
0.6776 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.677 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6765 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6757 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6747 |
Remote Similarity |
NPD37 |
Approved |
0.6746 |
Remote Similarity |
NPD6234 |
Discontinued |
0.674 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6733 |
Remote Similarity |
NPD1470 |
Approved |
0.6726 |
Remote Similarity |
NPD4966 |
Approved |
0.6726 |
Remote Similarity |
NPD4965 |
Approved |
0.6726 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6725 |
Remote Similarity |
NPD6808 |
Phase 2 |
0.671 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6705 |
Remote Similarity |
NPD3446 |
Phase 1 |
0.6687 |
Remote Similarity |
NPD6273 |
Approved |
0.6687 |
Remote Similarity |
NPD5049 |
Phase 3 |
0.6686 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6667 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD3412 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD1778 |
Approved |
0.6646 |
Remote Similarity |
NPD4476 |
Approved |
0.6646 |
Remote Similarity |
NPD4477 |
Approved |
0.6645 |
Remote Similarity |
NPD4307 |
Phase 2 |
0.6645 |
Remote Similarity |
NPD2861 |
Phase 2 |
0.6645
|
Remote Similarity |
NPD1612 |
Clinical (unspecified phase) |